Saturday, Pfizer (PFE) revealed the results from studies evaluating the company's investigational anti-insulin growth factor- type 1 receptor, or IGF-1R, antibody, figitumumab, in patients with non-small cell lung cancer, or NSCLC. A total of three abstracts were presented at the 45th Annual American Society of Clinical Oncology.
Lung cancer is the most common cancer worldwide. NSCLC accounts for about 85% of lung cancer cases and remains difficult to treat, particularly in the metastatic setting. Nearly 60% of NSCLC patients are diagnosed late with Stage IIIB/IV advanced disease. In Stage IV patients, the five-year survival rate is only 2%. For all stages of NSCLC, the five-year survival rate is only 15%.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.